Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan Children, in the context of vaccine vector efficacy

Vaccine

Volumn 27, Issue 27, 2009, Pages 3501-3504

  Dudareva, M ^a   Andrews, L ^a   Gilbert, S C ^a   Bejon, P ^b   Marsh, K ^b   Mwacharo, J ^b   Kai, O ^b   Nicosia, A ^c   Hill, A V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c Okairòs Srl ^*  (Italy)

Author keywords

Malaria vaccine; Simian adenoviral vector; Vector neutralizing antibodies

Indexed keywords

ADENOVIRUS VECTOR; ALKALINE PHOSPHATASE; CHIMPANZEE ADENOVIRUS 63 VECTOR; EPITOPE; HUMAN ADENOVIRUS 5 VECTOR; MALARIA VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADENOVIRUS; ANTIBODY TITER; CELLULAR IMMUNITY; CHILD; CHIMPANZEE ADENOVIRUS 63; COHORT ANALYSIS; HIGH RISK POPULATION; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IMMUNOGENICITY; KENYA; LETTER; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MORTALITY; NONHUMAN; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

ADENOVIRUSES, HUMAN; ADENOVIRUSES, SIMIAN; ANIMALS; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; GENETIC VECTORS; HUMANS; INFANT; MALARIA VACCINES; NEUTRALIZATION TESTS; PAN TROGLODYTES; SEROEPIDEMIOLOGIC STUDIES; VACCINATION; VACCINES, SYNTHETIC;

EID: 65649097335     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.080     Document Type: Letter

References (26)

1. Snow R.W., Guerra C.A., Noor A.M., Myint H.Y., and Hay S.I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434 (2005) 214-217
2. Rowe A.K., Rowe S.Y., Snow R.W., Korenromp E.L., Schellennerg J.R., Stein C., et al. The burden of malaria mortality among African children in the year 2000. Int J Epidemiol 35 (2006) 691-704
3. Clyde D.F., McCarthy V.C., Miller R.M., and Woodward W.E. Immunization of man against Falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 24 (1975) 397-401
4. Khusmith S., Sedegah M., and Hoffman S.L. Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2. Infect Immun 62 (1994) 2979-2983
5. Webster D.P., Dunachie S., Vuola J.M., Berthoud T., Keating S., Laidlaw S.M., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. PNAS USA 102 (2005) 4836-4841
6. Xiang Z.Q., Yang Y., Wilson J.M., and Ertl H.C.J. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219 (1996) 220-227
7. Casimiro D.R., Chen L., Fu T., Evans R.K., Caulfield M.J., Davies M., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77 (2003) 6305-6313
8. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194 (2006) 1638-1649
9. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170 (2003) 1416-1422
10. Tatsis N., Lin S.W., Harris-McCoy K., Garber D.A., Feinberg M.B., and Ertl H.C.J. Multiple immunizations with adenovirus and MVA vectors improve CD8(+) T cell functionality and mucosal homing. Virology 367 (2007) 156-167
11. Thorner A.R., Lemckert A.A.C., Goudsmit J., Lynch D.M., Ewald B.A., Denholtz M., et al. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J Virol 80 (2006) 12009-12016
12. Kobinger G.P., Feldmann H., Zhi Y., Schumer G., Gao G.P., Feldmann F., et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346 (2006) 394-401
13. Reyes-Sandoval A.S., Sridhar S., Berthoud T., Moore A.C., Harty J.T., Gilbert S.C., et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 38 (2008) 732-741
14. Abbink P., Lemckert A.A.C., Ewald B.A., Lynch D.M., Denholtz M., Smits S., et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81 (2007) 4654-4663
15. Capone S., Meola A., Ercole B.B., Vitelli A., Pezzanera M., Ruggeri L., et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 80 (2006) 1688-1699
16. Farina S.F., Gao G.P., Xiang Z.Q., Rux J.J., Burnett R.M., Alvira M.R., et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol 75 (2001) 11603-11613
17. Lemckert A.A.C., Grimbergen J., Smits S., Hartkoorn E., Holterman L., Berkhout B., et al. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol 87 (2006) 2891-2899
18. Thorner A.R., Vogels R., Kaspers J., Weverling G.J., Holterman L., and Lemckert A.A.C. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from Sub-Saharan Africa. J Clin Microbiol 44 (2006) 3781-3783
19. Roy S., Zhi Y., Kobinger G.P., Figueredo J., Calcedo R., Miller J.R., et al. Generation of an adenoviral vaccine vector based on simian adenovirus 21. J Gen Virol 87 (2006) 2477-2485
20. Mittereder N., March K.L., and Trapnell B.C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70 (1996) 7498-7509
21. Aste-Amézaga M., Bett A.J., Wang F., Casimiro D.R., Antonello J.M., Patel D.K., et al. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Human Gene Therapy 15 (2004) 293-304
22. Bejon P., Ogada E., Mwangi T., Milligan P., Lang T., Fegan G., et al. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS ONE 2 (2007) e707
23. Xiang Z.Q., Li Y., Cun A., Yang W., Ellenberg S., Switzer W.M., et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 12 (2006) 1596-1599
24. Bejon P., Mwacharo J., Kai O.K., Todryk S., Keating S., Lang T., et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 24 (2006) 4709-4715
25. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 372 (2008) 1894-1905
26. Chirmule N., Propert K.J., Magosin S.A., Qian Y., Qian R., and Wilson J.M. Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy 6 (1999) 1574-1585